Brokerages Set Apyx Medical Corporation (NASDAQ:APYX) PT at $6.50

Shares of Apyx Medical Corporation (NASDAQ:APYX) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $6.50.

APYX has been the subject of several research analyst reports. Roth Mkm initiated coverage on shares of Apyx Medical in a research note on Monday, December 15th. They issued a “buy” rating and a $6.00 price objective for the company. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, March 11th. Craig Hallum upped their price objective on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research note on Friday, March 27th.

Hedge Funds Weigh In On Apyx Medical

Several large investors have recently bought and sold shares of APYX. Fisher Asset Management LLC acquired a new position in Apyx Medical in the second quarter valued at $34,000. Nantahala Capital Management LLC boosted its stake in shares of Apyx Medical by 2.5% during the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after buying an additional 80,000 shares during the period. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical during the second quarter worth about $50,000. Salem Investment Counselors Inc. acquired a new stake in shares of Apyx Medical during the third quarter worth about $97,000. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in shares of Apyx Medical by 10.0% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 986,503 shares of the company’s stock worth $2,111,000 after buying an additional 89,767 shares during the period. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Stock Performance

Shares of APYX stock opened at $3.75 on Friday. The company has a current ratio of 5.00, a quick ratio of 4.26 and a debt-to-equity ratio of 2.35. Apyx Medical has a 12 month low of $0.83 and a 12 month high of $4.50. The company has a market cap of $156.86 million, a P/E ratio of -13.89 and a beta of 1.54. The firm has a fifty day moving average price of $3.72 and a 200 day moving average price of $3.54.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. The company had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Sell-side analysts predict that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.